In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Shell Canada's decision on whether to pursue Phase 2 of LNG Canada will depend on other opportunities that are available, ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with ...

Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial of TPIP in pulmonary arterial hypertension a “clear and ...

TuHURA Biosciences said its carcinoma therapy trials can continue now that health regulators have removed the partial clinical hold on the treatment tests.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

cCentre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health ...

Actuate's Phase 2 trial shows elraglusib/GnP improves overall survival in mPDAC patients, with a 37% lower death risk. Actuate Therapeutics presented promising results from its Phase 2 trial ...

and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...

President of Copper Peak Bob Jacquart said this first phase is focusing on the landing hill. “We’re going to redo the landing hill right now and get it, widen it, change the angle, and ...